Therapeutic Protein–Drug Interactions and Implications for Drug Development
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Many intrinsic and extrinsic factors can affect an individual patient's drug exposure and response. The US Food and Drug Administration (FDA) has published a number of guidances that recommend how and when to evaluate these factors during drug development. The most recent FDA draft guidance on drug interactions provides advice for in vitro and in vivo drug interaction studies, including suggestions for study design, dosing strategies and analysis, and interpretation of data for medical product labels. The draft guidance updated the FDA's recommendations on the evaluation of important cytochrome P450 (CYP) enzyme- and transporter-based drug interactions during drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Self-citationDrug interactions evaluation: An integrated part of risk assessment of therapeutics
Zhang, L., Reynolds, K. S., Zhao, P., & Huang, S.-M. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.12.016 · Cited by 125
Self-citation
Cited by
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Rowland, M., Peck, C., & Tucker, G. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100540 · Cited by 662
Dupilumab: A review of its use in the treatment of atopic dermatitis
Gooderham, M. J., Hong, H. C.-H., Eshtiaghi, P., & Papp, K. A. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.12.022 · Cited by 343
Integrated gut/liver microphysiological systems elucidates inflammatory inter‐tissue crosstalk
Chen, W. L. K., Edington, C., Suter, E., Yu, J., Velazquez, J. J., Velazquez, J. G., Shockley, M., Large, E. M., Venkataramanan, R., Hughes, D. J., et al. (2017) · Biotechnology and Bioengineering · doi:10.1002/bit.26370 · Cited by 172
The Role of Physiologically Based Pharmacokinetic Modeling in Regulatory Review
Huang, S.-M., & Rowland, M. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.320 · Cited by 150
Drug interactions evaluation: An integrated part of risk assessment of therapeutics
Zhang, L., Reynolds, K. S., Zhao, P., & Huang, S.-M. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.12.016 · Cited by 125
Self-citation
Metadata
- Authors
- Huang, S.-M., Zhao, H., Lee, J.-I., Reynolds, K., Zhang, L., Temple, R., & Lesko, L. J.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2010-03-03
- Volume
- 87
- Issue
- 4
- Pages
- 497-503
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2097742807
- Cited by
- 141
- References
- 3
- FWCI
- 15.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic Protein–Drug Interactions and Implications for Drug Development. https://app.cochat.ai/papers/10.1038/clpt.2009.308
- The paper
- Huang, S.-M., Zhao, H., Lee, J.-I., Reynolds, K., Zhang, L., Temple, R., & Lesko, L. J. (2010). Therapeutic Protein–Drug Interactions and Implications for Drug Development. Clinical Pharmacology & Therapeutics. https://doi.org/10.1038/clpt.2009.308
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.